Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $118.25.

A number of equities research analysts have recently issued reports on ENTA shares. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $80.00 to $120.00 in a research note on Tuesday. Finally, BidaskClub upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 24th.

ENTA stock traded up $0.45 on Monday, reaching $87.68. 1,605 shares of the company’s stock were exchanged, compared to its average volume of 183,994. Enanta Pharmaceuticals has a twelve month low of $64.08 and a twelve month high of $127.77. The firm has a market capitalization of $1.73 billion, a PE ratio of 25.20 and a beta of 1.38.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.46 by ($0.21). Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The business had revenue of $69.89 million for the quarter, compared to analyst estimates of $71.27 million. During the same period in the prior year, the company earned $0.59 EPS. The company’s revenue was up 83.4% on a year-over-year basis. On average, equities research analysts anticipate that Enanta Pharmaceuticals will post 1.51 earnings per share for the current year.

In other Enanta Pharmaceuticals news, VP Nathaniel S. Gardiner sold 3,270 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $95.28, for a total transaction of $311,565.60. Following the completion of the sale, the vice president now owns 320,169 shares in the company, valued at approximately $30,505,702.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce L. A. Carter sold 1,546 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $99.16, for a total value of $153,301.36. Following the sale, the director now owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,514 shares of company stock valued at $5,632,849. 11.35% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ENTA. PNC Financial Services Group Inc. raised its stake in Enanta Pharmaceuticals by 64.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 249 shares in the last quarter. Financial Gravity Wealth Inc. bought a new stake in Enanta Pharmaceuticals during the 1st quarter valued at $49,000. Bank of Montreal Can raised its stake in Enanta Pharmaceuticals by 33.0% during the 4th quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 216 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in Enanta Pharmaceuticals by 196.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 829 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 549 shares in the last quarter. Finally, Pacer Advisors Inc. bought a new stake in Enanta Pharmaceuticals during the 3rd quarter valued at $230,000. Hedge funds and other institutional investors own 86.55% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Recommended Story: What is a stock buyback?

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.